News Column

GSK -Results announcement for the first quarter 2014

May 1, 2014

ENP Newswire - 01 May 2014

Release date- 30042014 - Q1 turnover GBP5.6 billion, -2% (CER) on an ex-divestment* basis.

View full Q1 2014 results (PDF):

.Pharmaceutical and Vaccines sales growth in all major regions except US: Europe +3%, Emerging Markets +2%, Japan +13%. US (-10%) impacted by continued competition in respiratory market and quarterly volatility in wholesaler/retailer stocking patterns

.HIV sales +4%, driven by uptake of recently launched integrase inhibitor, Tivicay

.Vaccines sales +3%, with US growth partly offset by phasing of tenders in Emerging Markets

.Consumer Healthcare sales flat with Rest of World growth (+6%) offsetting the impact in US and Europe of temporary supply interruptions to certain products

.Core EPS 21.0p (+2% CER) driven by operating leverage and financial efficiencies

.Continued progress in strategy to renew and diversify respiratory portfolio

.Continued R&D momentum expected to continue with around 40 NMEs currently in phase II/III clinical development

.First quarter dividend +6% to 19p. Share buy backs of GBP1-2 billion targeted during 2014

.Full year guidance of core EPS growth of 4-8% CER reiterated. Sales expected to grow in CER terms and on an ex-divestment basis

.Major three-part transaction announced with Novartis intended to strengthen sustainability of Group sales base and improve long term earnings outlook. Completion, subject to shareholder and regulatory approval, expected by H1 2015

For more stories on investments and markets, please see HispanicBusiness' Finance Channel

Source: ENP Newswire